Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZD6474 (Zactima) plus Arimidex versus Arimidex alone as 2nd-line therapy for hormone-sensitive advanced breast cancer
2005-003591-38Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in breast cancer comparing ZD6474 (Zactima) + Arimidex with Placebo + Arimidex (2 arms). Primary endpoint: Objective disease progression. Started Oct 2005; status: terminated.
02
Drugs
vandetanib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2005-003591-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003591-38.